BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2868 related articles for article (PubMed ID: 7891228)

  • 21. Effect of heat shock on the expression of urokinase-type plasminogen activator receptor in human umbilical vein endothelial cells.
    Fukao H; Hagiya Y; Ueshima S; Okada K; Takaishi T; Izaki S; Matsuo O
    Thromb Haemost; 1996 Feb; 75(2):352-8. PubMed ID: 8815589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression.
    Robert C; Bolon I; Gazzeri S; Veyrenc S; Brambilla C; Brambilla E
    Clin Cancer Res; 1999 Aug; 5(8):2094-102. PubMed ID: 10473092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
    Nishikawa M; Stapleton PP; Freeman TA; Gaughan JP; Matsuda T; Daly JM
    J Am Coll Surg; 2004 Sep; 199(3):428-35. PubMed ID: 15325613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ethanol-induced up-regulation of the urokinase receptor in cultured human endothelial cells.
    Tabengwa EM; Grenett HE; Benza RL; Abou-Agag LH; Tresnak JK; Wheeler CG; Booyse FM
    Alcohol Clin Exp Res; 2001 Feb; 25(2):163-70. PubMed ID: 11236828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro.
    Paciucci R; Torà M; Díaz VM; Real FX
    Oncogene; 1998 Feb; 16(5):625-33. PubMed ID: 9482108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Breast cancer: prognostic value of a dissemination index based on 4 components of the urokinase-type plasminogen activator system].
    Bouchet C; Hacène K; Martin PM; Becette V; Tubiana-Hulin M; Lasry S; Oglobine J; Spyratos F
    Pathol Biol (Paris); 2000 Nov; 48(9):825-31. PubMed ID: 11141918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma.
    Häckel C; Czerniak B; Ayala AG; Radig K; Roessner A
    Cancer; 1997 Jan; 79(1):53-8. PubMed ID: 8988726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tetranectin and plasmin/plasminogen are similarly distributed at the invasive front of cutaneous melanoma lesions.
    De Vries TJ; De Wit PE; Clemmensen I; Verspaget HW; Weidle UH; Bröcker EB; Ruiter DJ; Van Muijen GN
    J Pathol; 1996 Jul; 179(3):260-5. PubMed ID: 8774480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasminogen activators and inhibitors are transcribed during early macaque implantation.
    Feng Q; Liu K; Liu YX; Byrne S; Ockleford CD
    Placenta; 2001; 22(2-3):186-99. PubMed ID: 11170823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
    J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein.
    Margheri F; D'Alessio S; Serratì S; Pucci M; Del Rosso A; Benelli R; Ferrari N; Noonan DM; Albini A; Fibbi G; Del Rosso M
    Int J Oncol; 2005 Jul; 27(1):223-35. PubMed ID: 15942664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma.
    De Petro G; Tavian D; Copeta A; Portolani N; Giulini SM; Barlati S
    Cancer Res; 1998 May; 58(10):2234-9. PubMed ID: 9605771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The plasminogen-plasminogen activator (PA) system in neuroblastoma: role of PA inhibitor-1 in metastasis.
    Sugiura Y; Ma L; Sun B; Shimada H; Laug WE; Seeger RC; DeClerck YA
    Cancer Res; 1999 Mar; 59(6):1327-36. PubMed ID: 10096567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer.
    Casslén B; Bossmar T; Lecander I; Astedt B
    Eur J Cancer; 1994; 30A(9):1302-9. PubMed ID: 7999418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer.
    Ganesh S; Sier CF; Heerding MM; van Krieken JH; Griffioen G; Welvaart K; van de Velde CJ; Verheijen JH; Lamers CB; Verspaget HW
    Br J Cancer; 1997; 75(12):1793-801. PubMed ID: 9192984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2].
    Mengele K; Harbeck N; Reuning U; Magdolen V; Schmitt M
    Hamostaseologie; 2005 Aug; 25(3):301-10. PubMed ID: 16113755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.
    Schacke W; Beck KF; Pfeilschifter J; Koch F; Hattenbach LO
    Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2799-805. PubMed ID: 12147618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
    Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
    Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression and localisation of extracellular matrix degrading proteases and their inhibitors during the oestrous cycle and after induced luteolysis in the bovine corpus luteum.
    Kliem H; Welter H; Kraetzl WD; Steffl M; Meyer HH; Schams D; Berisha B
    Reproduction; 2007 Sep; 134(3):535-47. PubMed ID: 17709571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 144.